Santhera valuation report "Vamoro-alone"

Monday, November 23, 2020 @ 12:00 am

Despite the Puldysa setback, we believe Santhera provides ample equity upside. Positive results of the pivotal “VISION-DMD” trial of vamorolone in DMD in Q2 2021 will be transformational for Santhera with a sharp re-rating. Santhera can now monetize non-DMD indications to replenish its current cash position that reaches up to Q2 2021.

Key catalysts include:

Lonodelestat MAD trial results (Q1 2021)
Vamorolone pivotal “VISION-DMD” trial results (Q2 2021)
Vamorolone US DMD filing (Q4 2021)

Go to the Santhera Valuation Report "Vamoro-alone"

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We recently noticed fraudulent emails to steal your passwords of your Microsoft, Outlook or similar accounts via phishing emails. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals will ask y
October 8, 2024

Pharvaris' strategic priorities in 2025

Initiated CHAPTER-3, the pivotal Phase 3 study of deucrictibant for prophylaxis against hereditary angioedema (HAE) attacks in 2024; topline data anticipated in 2H2026 Enrollment in RAPIDe-3, the pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, continuing as planned; topline data anticipated in 1Q2026 Study initiation of deucrictibant for the treatment of acquired
January 13, 2025

Sophia Genetics: ISO certifications for information security and privacy protection

Company reaffirms its commitment to information security and data protection in healthcare technology
January 9, 2025

Cytosurge: Strategic leadership transition

Cytosurge AG announces a leadership transition effective January 1, 2025. Co-founder Pascal Behr steps down as CEO after 12 years to join the Board as Delegate. Simon Egli, former Chief Commercial Officer, becomes CEO to lead the next growth phase. Under Behr, Cytosurge achieved milestones like 140+ FluidFM systems installed and 150+ publications. Egli, a biotech veteran, aims to advance innovatio
January 9, 2025

LimmaTech awarded FDA fast track designation for vaccine against Staphylococcus aureus

LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to LimmaTech’s multivalent toxoid vaccine candidate, LBT-SA7, designed to prevent skin and soft tissue infections (SSTIs) caused by the bacterial pathogen, Staphylococcus a
December 19, 2024

Vandria becoming clinical stage company: First clinical trial for neurodegenerative disorders

Vandria SA, a company at the vanguard of mitochondrial therapeutics developing first-in-class small molecule mitophagy inducers, today announces that the first subjects have been dosed in its first-in-human clinical trial of its lead Central Nervous System (CNS) compound VNA-318. Readout of this combined single and multiple ascending dose trial is expected in the summer of 2025.
December 18, 2024